Junji Tsurutani

J-GLOBAL         Last updated: Oct 12, 2019 at 20:55
Junji Tsurutani
Showa University
School of Medicine
Research funding number

Research Areas


Academic & Professional Experience

Aug 2018
Head, professor, Advvanced Cancer Translational Research Institute, Showa University
Jan 2008
Jul 2018
Assosiate professor, Department of Medical Oncology, Kindai University Faculty of Medicine
Apr 2001
Mar 2007
Graduate student, control of infection diseases unit, Nagasaki University,Graduate School of Medicine
Jul 2002
Jul 2006
Research fello, National Cancer Institute, National Institute of Health (USA)
Apr 1999
Mar 2001
Assistant professor, Department of Internal Medicine, Kindai University Faculty of Medicine

Awards & Honors

Apr 2016
cfDNA analysis in HER2 positve breast cancer, Research Award, Japanese Society of Clinical Oncology
Oct 2015
Phase I study of nab-paclitaxel and S-1 in ABC, Research Award, Kindai Univ. Medical Association
Sep 2013
Travel Award, Lynn Sage Cancer Symposium (Chicago)

Published Papers

Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small cell lung
Junji Tsurutani
Ann Oncol.      Sep 2019   [Refereed]
Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors.
Junji Tsurutani
Anticancer Res.   39(9) 5195-5201   Sep 2019   [Refereed]
Blockade of EGFR Activation Promotes TNF-Induced Lung Epithelial Cell Apoptosis and Pulmonary Injury.
Junji Tsurutani
Int J Mol Sci.   20(16)    Aug 2019   [Refereed]
A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing.
Junji Tsurutani
Sci Rep. 2019 Aug 5;9(1):11340.   9(1) 11340   Aug 2019   [Refereed]
A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer.
Junji Tsurutani
Transl Lung Cancer Res.   8(3) 247-257   Jun 2019   [Refereed]
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib.
Junji Tsurutani
J Vis Exp.      Jun 2019   [Refereed]
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
Junji Tsurutani
Lancet Oncol.   20(6) 827-836   Jun 2019   [Refereed]
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Junji Tsurutani
Lancet Oncol.   20(6) 816-826   Jun 2019   [Refereed]
[fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification.
Junji Tsurutani
Int J Cancer.      May 2019   [Refereed]
Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
Junji Tsurutani
Cancer Med. 2019 Mar;8(3):1258-1268   8(3) 1258-1268   Mar 2019   [Refereed]
aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.
Junji Tsurutani
Oncologist. 2019 Mar;24(3):327-337.   24(3) 327-337   Mar 2019   [Refereed]
Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study.
Junji Tsurutani
Breast Cancer. 26(2):235-243   26(2) 235-243   Mar 2019   [Refereed]
Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer.
Junji Tsurutani
Cancer Sci.   110(1) 52-60   Jan 2019   [Refereed]
KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR.
Junji Tsurutani
18(1) 112-126   Jan 2019   [Refereed]
HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer.
Junji Tsurutani
Breast Cancer   25(5) 605-613   Sep 2018   [Refereed]
A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP.
Junji Tsurutani
Breast   40 67-75   Aug 2018   [Refereed]
Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study).
Junji Tsurutani
BMC Cancer   17(1) 674   Oct 2017   [Refereed]
Prospective replication study implicates the catechol-O-methyltransferase Val158Met polymorphism as a biomarker for the response to morphine in patients with cancer.
Matsuoka H, Makimura C, Koyama A, Fujita Y, Tsurutani J, Sakai K, Sakamoto R, Nishio K, Nakagawa K.
Biomed Rep   7(4) 380-384   Oct 2017   [Refereed]
Increased risk of SSEs in bone-only metastatic breast cancer patients treated with zoledronic acid.
Yanae M, Fujimoto S, Tane K, Tanioka M, Fujiwara K, Tsubaki M, Yamazoe Y, Morishima Y, Chiba Y, Takao S, Komoike Y, Tsurutani J, Nakagawa K, Nishida S.
J Bone Oncol   31(8) 18-22   Aug 2017   [Refereed]
Expectation of a Decrease in Pain Affects the Prognosis of Pain in Cancer Patients: a Prospective Cohort Study of Response to Morphine.
Matsuoka H, Yoshiuchi K, Koyama A, Makimura C, Fujita Y, Tsurutani J, Sakai K, Sakamoto R, Nishio K, Nakagawa K.
Int J Behav Med.      Aug 2017   [Refereed]
T790M-selective EGFR-TKI combined with dasatinib as an optimal strategy for overcoming EGFR-TKI resistance in T790M-positive non-small cell lung cancer.
Watanabe S, Yoshida T, Kawakami H, Takegawa N, Tanizaki J, Hayashi H, Takeda M, Yonesaka K, Tsurutani J, Nakagawa K.
Mol Cancer Ther      Aug 2017   [Refereed]
Junji TsurutaniTakegawa N, Nonagase Y, Yonesaka K, Sakai K, Maenishi O, Ogitani Y, Tamura T, Nishio K, Nakagawa K, Tsurutani J.
Int J Cancer.      Jul 2017   [Refereed]
Lentinula edodes mycelia extract plus adjuvant chemotherapy for breast cancer patients: Results of a randomized study on host quality of life and immune function improvement.
Nagashima Y, Yoshino S, Yamamoto S, Maeda N, Azumi T, Komoike Y, Okuno K, Iwasa T, Tsurutani J, Nakagawa K, Masaaki O, Hiroaki N.
Mol Clin Oncol      Jul 2017   [Refereed]
Gemcitabine and Vinorelbine Combination Chemotherapy in Taxane-Pretreated Patients with Metastatic Breast Cancer: A Phase II Study of the Kinki Multidisciplinary Breast Oncology Group (KMBOG) 1015.
Yamamura J, Masuda N, Yamamoto D, Tsuyuki S, Yamaguchi M, Tanaka S, Tsurutani J, Tokunaga S, Yoshidome K, Mizutani M, Aono T, Ooe A, Tanino H, Matsunami N, Yasojima H, Nakayama T, Nishida Y.
Chemotherapy      Jun 2017   [Refereed]
Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study.
Watanabe J, Ito Y, Ohsumi S, Mizutani M, Tashiro H, Sakurai K, Takahashi M, Saito T, Tsurutani J, Mukai H, Yoshinami T, Takao S, Yamamoto Y, Matsuoka T, Iwase H, Iwata H, Nakamura S, Saeki T.
Invest New Drugs      Jun 2017   [Refereed]
Clinical evaluation of palliative chemoradiotherapy for metastatic esophageal cancer.
Junji Tsurutani
Oncotarget   8(46) 80286-80294   May 2017   [Refereed]
Nonagase Y, Yonesaka K, Kawakami H, Watanabe S, Haratani K, Takahama T, Takegawa N, Ueda H, Tanizaki J, Hayashi H, Yoshida T, Takeda M, Chiba Y, Tamura T, Nakagawa K, Tsurutani J.
Oncotarget   7(51) 84860-84871   Dec 2016   [Refereed]
Watanabe S, Takeda M, Takahama T, Iwasa T, Tsurutani J, Tanizaki J, Shimizu T, Sakai K, Wada Y, Isogai N, Nishio K, Nakagawa K.
Invest New Drugs      Jun 2016   [Refereed]
Shimizu T, Seto T, Hirai F, Takenoyama M, Nosaki K, Tsurutani J, Kaneda H, Iwasa T, Kawakami H, Noguchi K, Shimamoto T, Nakagawa K.
Invest New Drugs.      Jun 2016   [Refereed]
Aihara T, Toyama T, Takahashi M, Yamamoto Y, Hara F, Akabane H, Fujisawa T, Ishikawa T, Nagai S, Nakamura R, Tsurutani J, Ito Y, Mukai H.
Breast Cancer      May 2016   [Refereed]
Nonagase Y, Okamoto K, Iwasa T, Yoshida T, Tanaka K, Takeda M, Kaneda H, Shimizu T, Tsurutani J, Nakagawa K.
Anticancer Drugs      Mar 2016   [Refereed]
Takashima T, Mukai H, Hara F, Matsubara N, Saito T, Takano T, Park Y, Toyama T, Hozumi Y, Tsurutani J, Imoto S, Watanabe T, Sagara Y, Nishimura R, Shimozuma K, Ohashi Y
Lancet Oncol      Jan 2016   [Refereed]
Takegawa N, Yonesaka K, Sakai K, Ueda H, Watanabe S, Nonagase Y, Okuno T, Takeda M, Maenishi O, Tsurutani J, Satoh T, Okamoto I, Nishio K, Tamura T, Nakagawa K.
Oncotarget      Jan 2016   [Refereed]
Tsurutani J, Kuroi K, Iwasa T, Miyazaki M, Nishina S, Makimura C, Tanizaki J, Okamoto K, Yamashita T, Aruga T, Shigekawa T, Komoike Y, Saeki T, Nakagawa K.
Cancer Sci      Jun 2015   [Refereed]
Sakai K, Tsurutani J, Yamanaka T, Yoneshige A, Ito A, Togashi Y, De Velasco MA, Terashima M, Fujita Y, Tomida S, Tamura T, Nakagawa K, Nishio K.
PLoS One      May 2015   [Refereed]
Fujisaka Y, Kurata T, Tanaka K, Kudo T, Okamoto K, Tsurutani J, Kaneda H, Okamoto I, Namiki M, Kitamura C, Nakagawa K.
Invest New Drugs      Apr 2015   [Refereed]
Sakiyama T, Tsurutani J, Iwasa T, Kawakami H, Nonagase Y, Yoshida T, Tanaka K, Fujisaka Y, Kurata T, Komoike Y, Nishio K, Nakagawa K.
Br J Cancer      Mar 2015   [Refereed]
Okamoto I, Miyazaki M, Takeda M, Terashima M, Azuma K, Hayashi H, Kaneda H, Kurata T, Tsurutani J, Seto T, Hirai F, Konishi K, Sarashina A, Yagi N, Kaiser R, Nakagawa K.
J Thorac Oncol      Feb 2015   [Refereed]
Mukai H, Aihara T, Yamamoto Y, Takahashi M, Toyama T, Sagara Y, Yamaguchi H, Akabane H, Tsurutani J, Hara F, Fujisawa T, Yamamoto N, Ohsumi S
Breast Cancer      Jan 2015   [Refereed]
Kurata T, Tsurutani J, Fujisaka Y, Okamoto W, Hayashi H, Kawakami H, Shin E, Hayashi N, Nakagawa K.
Invest New Drugs      Oct 2014   [Refereed]
Tanioka M, Sasaki M, Shimomura A, Fujishima M, Doi M, Matsuura K, Sakuma T, Yoshimura K, Saeki T, Ohara M, Tsurutani J, Watatani M, Takano T, Kawabata H, Mukai H, Naito Y, Hirokaga K, Takao S, Minami H.
Breast      Aug 2014   [Refereed]
Terashima M, Sakai K, Togashi Y, Hayashi H, De Velasco MA, Tsurutani J, Nishio K.
Springerplus      Aug 2014   [Refereed]
Phase II study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer.
Takashima T, Nakayama T, Yoshidome K, Kawajiri H, Kamigaki S, Tsurutani J, Arai T, Ito T, Komoike Y, Doi T, Masuda N, Miyauchi K, Miyoshi Y, Sakamoto J, Morita S, Taguchi T.
Anticancer Res      Jul 2014   [Refereed]
Kidera Y, Kawakami H, Sakiyama T, Okamoto K, Tanaka K, Takeda M, Kaneda H, Nishina S, Tsurutani J, Fujiwara K, Nomura M, Yamazoe Y, Chiba Y, Nishida S, Tamura T, Nakagawa K.
PLoS One      Jul 2014   [Refereed]
Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer.
Kawabata S, Chiang CT, Tsurutani J, Shiga H, Arwood ML, Komiya T, Gills JJ, Memmott RM, Dennis PA.
Oncotarget      Feb 2014   [Refereed]
Matsuoka H, Tsurutani J, Tanizaki J, Iwasa T, Komoike Y, Koyama A, Nakagawa K.
BMC Res Notes      Dec 2013   [Refereed]
Discussion about Biomilar development: Filgrastim BS injection and its applications in clinical practice.
Saeki T, Tokuda Y, Takigawa N, Tsurutani J.
Gan To Kagaku Ryoho      Oct 2013
Hasegawa Y, Okamoto I, Takezawa K, Miyazaki M, Tsurutani J, Yonesaka K, Morinaga R, Tsuya A, Terashima M, Kudoh T, Azuma K, Kurata T, Nishikawa T, Fukuoka M, Nishimura Y, Nakagawa K.
Invest New Drugs      Jun 2013   [Refereed]
Kazuhiko Nakagawa, Junji Tsurutani
Chin Clin Oncol      Dec 2012   [Invited]
Resistant mechanisms against breast cancer treatment and therapeutic strategies].
Junko Tanizaki, Junji Tsurutani
Nihon Rinsho      Nov 2012
Matsuoka H, Arao T, Makimura C, Takeda M, Kiyota H, Tsurutani J, Fujita Y, Matsumoto K, Kimura H, Otsuka M, Koyama A, Imamura CK, Tanigawara Y, Yamanaka T, Tanaka K, Nishio K, Nakagawa K.
Oncol Rep      May 2012   [Refereed]
Azuma K, Kawahara A, Hattori S, Taira T, Tsurutani J, Watari K, Shibata T, Murakami Y, Takamori S, Ono M, Izumi H, Kage M, Yanagawa T, Nakagawa K, Hoshino T, Kuwano M.
J Thorac Oncol      May 2012   [Refereed]
Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin.
Matsuoka H, Makimura C, Koyama A, Otsuka M, Okamoto W, Fujisaka Y, Kaneda H, Tsurutani J, Nakagawa K.
Anticancer Res      May 2012   [Refereed]
Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.
Jpn J Clin Oncol 2012   42(6) 528-533   Jun 2012   [Refereed]
Prospective study evaluating the plasma concentrations of twenty-six cytokines and response to morphine treatment in cancer patients.
Makimura C, Arao T, Matsuoka H, Takeda M, Kiyota H, Tsurutani J, Fujita Y, Matsumoto K, Kimura H, Otsuka M, Koyama A, Imamura CK, Yamanaka T, Tanaka K, Nishio K, Nakagawa K.
Anticancer Res      Dec 2011   [Refereed]
Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B.
Hayashi H, Tsurutani J, Satoh T, Masuda N, Okamoto W, Morinaga R, Terashima M, Miyazaki M, Okamoto I, Nishida Y, Tominaga S, Tokunaga Y, Yamaguchi M, Sakamoto J, Nakayama T, Nakagawa K.
Breast Cancer      Nov 2011   [Refereed]
Zhang C, Elkahloun AG, Robertson M, Gills JJ, Tsurutani J, Shih JH, Fukuoka J, Hollander MC, Harris CC, Travis WD, Jen J, Dennis PA.
PLoS One      Aug 2011   [Refereed]
Kidera Y, Satoh T, Ueda S, Okamoto W, Okamoto I, Fumita S, Yonesaka K, Hayashi H, Makimura C, Okamoto K, Kiyota H, Tsurutani J, Miyazaki M, Yoshinaga M, Fujiwara K, Yamazoe Y, Moriyama K, Tsubaki M, Chiba Y, Nishida S, Nakagawa K.
Int J Clin Oncol.      Jun 2011   [Refereed]
Azuma K, Tsurutani J, Sakai K, Kaneda H, Fujisaka Y, Takeda M, Watatani M, Arao T, Satoh T, Okamoto I, Kurata T, Nishio K, Nakagawa K.
Biochem Biophys Res Commun      Apr 2011   [Refereed]
Hirao A, Oiso N, Tsurutani J, Kimura M, Watatani M, Nakagawa K, Kawada A.
Case Rep Dermatol      Feb 2011   [Refereed]
Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors.
Okamoto I, Shimizu T, Miyazaki M, Tsurutani J, Ichikawa Y, Terashima M, Takeda M, Fumita S, Ohki E, Kimura N, Hashimoto J, Nakagawa K.
Invest New Drugs      Oct 2010   [Refereed]
Kurata T, Yamamoto N, Komiya T, Tsurutani J, Miyazaki M, Tamura K, Takeda K, Nakagawa K, Fukuoka M.
Japanese Journal of Clinical Oncology   40(10) 992-994   Jun 2010   [Refereed]
FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth.
Kaneda H, Arao T, Tanaka K, Tamura D, Aomatsu K, Kudo K, Sakai K, De Velasco MA, Matsumoto K, Fujita Y, Yamada Y, Tsurutani J, Okamoto I, Nakagawa K, Nishio K.
Cancer Res      Feb 2010   [Refereed]
Does escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer.
Lung Cancer   70(2) 168-173   2010
Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M
Lancet Oncol   11(2) 121-128   Dec 2009   [Refereed]
Okamoto K, Tsurutani J, Terashima M, Okamoto I, Nakagawa K.
Ann Oncol      Mar 2009   [Refereed]
Lemierre's syndrome followed by acute respiratory distress syndrome successfully rescued by antibiotics and hemoperfusion with polymyxin B-immobilized fiber.
Takazono T, Izumikawa K, Tsurutani J, Tanaka A, Kakugawa T, Fukuda Y, Saito M, Kurihara S, Imamura Y, Seki M, Kakeya H, Yamamoto Y, Yanagihara K, Kohno S.
Jpn J Infect Dis      Mar 2009   [Refereed]
Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, Borojerdi J, Warfel NA, Gardner ER, Danish M, Hollander MC, Kawabata S, Tsokos M, Figg WD, Steeg PS, Dennis PA.
Clin Cancer Res      Sep 2007   [Refereed]
Granville CA, Warfel N, Tsurutani J, Hollander MC, Robertson M, Fox SD, Veenstra TD, Issaq HJ, Linnoila RI, Dennis PA.
Clin Cancer Res      Apr 2007   [Refereed]
Tsurutani J, Steinberg SM, Ballas M, Robertson M, LoPiccolo J, Soda H, Kohno S, Egilsson V, Dennis PA.
Lung Cancer.      Nov 2006   [Refereed]
Kinoshita A, Fukuda M, Soda H, Nagashima S, Fukuda M, Takatani H, Kuba M, Nakamura Y, Tsurutani J, Kohno S, Oka M
Br J Cancer      May 2006   [Refereed]
Tsurutani J, Ballas M, Steinberg SM, Egilsson V, Dennis PA.
Lancet      Jan 2006
Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer.
Yamamoto N, Tsurutani J, Yoshimura N, Asai G, Moriyama A, Nakagawa K, Kudoh S, Takada M, Minato Y, Fukuoka M.
Anticancer Res      Jan 2006   [Refereed]
Tsurutani J, Fukuoka J, Tsurutani H, Shih JH, Hewitt SM, Travis WD, Jen J, Dennis PA.
J Clin Oncol      Dec 2005   [Refereed]
Kitazaki T, Oka M, Nakamura Y, Tsurutani J, Doi S, Yasunaga M, Takemura M, Yabuuchi H, Soda H, Kohno S.
Lung Cancer      Sep 2005   [Refereed]
Coxon A, Rozenblum E, Park YS, Joshi N, Tsurutani J, Dennis PA, Kirsch IR, Kaye FJ.
Cancer Res      Aug 2005   [Refereed]
Tsurutani J, Castillo SS, Brognard J, Granville CA, Zhang C, Gills JJ, Sayyah J, Dennis PA.
Carcinogenesis      Mar 2005   [Refereed]
Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, Ikegami Y, Tsurutani J, Nakatomi K, Kitazaki T, Doi S, Yoshida H, Kohno S.
Cancer Res      Feb 2005   [Refereed]
Tsurutani J, Dennis PA.
J Natl Cancer Inst      Dec 2004   [Refereed]
Fiala ES, Sohn OS, Wang CX, Seibert E, Tsurutani J, Dennis PA, El-Bayoumy K, Sodum RS, Desai D, Reinhardt J, Aliaga C.
Carcinogenesis      Dec 2004   [Refereed]
The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells.
Doi S, Soda H, Oka M, Tsurutani J, Kitazaki T, Nakamura Y, Fukuda M, Yamada Y, Kamihira S, Kohno S.
Mol Cancer Ther      Nov 2004   [Refereed]
Fukuda M, Oka M, Soda H, Kinoshita A, Fukuda M, Nagashima S, Kuba M, Takatani H, Tsurutani J, Nakamura Y, Kasai T, Inoue Y, Soejima Y, Kohno S;
Cancer Chemother Pharmacol      Sep 2004   [Refereed]
Autoimmunity to heat shock protein 40 in ulcerative colitis.
Sato S, Oka M, Noguchi Y, Soda H, Tsurutani J, Nakamura Y, Kitazaki T, Mizuta Y, Takeshima F, Murase K, Murata I, Ohtsuka K, Kohno S
J Int Med Res      May 2004   [Refereed]
Castillo SS, Brognard J, Petukhov PA, Zhang C, Tsurutani J, Granville CA, Li M, Jung M, West KA, Gills JG, Kozikowski AP, Dennis PA.
Cancer Res      Apr 2004   [Refereed]
Shiozawa K, Oka M, Soda H, Yoshikawa M, Ikegami Y, Tsurutani J, Nakatomi K, Nakamura Y, Doi S, Kitazaki T, Mizuta Y, Murase K, Yoshida H, Ross DD, Kohno S.
Int J Cancer.      Jan 2004   [Refereed]
Expression and functional analyses of breast cancer resistance protein in lung cancer.
Kawabata S, Oka M, Soda H, Shiozawa K, Nakatomi K, Tsurutani J, Nakamura Y, Doi S, Kitazaki T, Sugahara K, Yamada Y, Kamihira S, Kohno S.
Clin Cancer Res      Aug 2003   [Refereed]
Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, Tsurutani J, Dennis PA, Mills GB, Arteaga CL.
Oncogene      May 2003   [Refereed]
Tsurutani J, Soda H, Oka M, Suenaga M, Doi S, Nakamura Y, Nakatomi K, Shiozawa K, Amada YY, Kamihira S, Kohno S.
Nagasaki University School of Medicine   104(2) 238-242   Mar 2003   [Refereed]
Oka M, Fukuda M, Kuba M, Ichiki M, Rikimaru T, Soda H, Tsurutani J, Nakamura Y, Kawabata S, Nakatomi K, Narasaki F, Nagashima S, Takatani H, Fukuda M, Kinoshita A, Kohno S.
Eur J Cancer      Oct 2002   [Refereed]
Kasai T, Oka M, Soda H, Tsurutani J, Fukuda M, Nakamura Y, Kawabata S, Nakatomi K, Nagashima S, Takatani H, Fukuda M, Kinoshita A, Kohno S.
Eur J Cancer      Sep 2002   [Refereed]
Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan.
Tsurutani J, Nitta T, Hirashima T, Komiya T, Uejima H, Tada H, Syunichi N, Tohda A, Fukuoka M, Nakagawa K.
Lung Cancer      Mar 2002   [Refereed]
Tsurutani J, Komiya T, Uejima H, Tada H, Syunichi N, Oka M, Kohno S, Fukuoka M, Nakagawa K.
Lung Cancer      Jan 2002   [Refereed]
Oka M, Fukuda M, Nagashima S, Fukuda M, Kinoshita A, Soda H, Doi S, Narasaki F, Suenaga M, Takatani H, Nakamura Y, Kawabata S, Tsurutani J, Kanda T, Kohno S.
Cancer Chemother Pharmacol.      Dec 2001   [Refereed]
A case of multidrug-resistant pulmonary tuberculosis.
Tsurutani J, Sohda H, Oka M, Kohno S
Nihon Kokyuki Gakkai Zasshi      Aug 2000   [Refereed]
Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers.
Fukuda M, Oka M, Soda H, Terashi K, Kawabata S, Nakatomi K, Takatani H, Tsurutani J, Tsukamoto K, Noguchi Y, Fukuda M, Kinoshita A, Kohno S.
Clin Cancer Res      Dec 1999   [Refereed]
A case of pulmonary actinomycosis marked by diagnostic difficulty
Tsurutani J, Tominaga M, Furukawa T, Fukuda M, Soda H, Oka M, Kohno S.
Nihon Kokyuki Gakkai Zasshi      Nov 1999
Tsurutani J, Kinoshita A, Kaida H, Fujii H, Narasaki F, Fukuda M, Oka M, Kohno S.
Intern Med      Mar 1999
Oka M, Fukuda M, Terashi K, Takatani H, Narasaki F, Nakano R, Tsurutani J, Nakamura Y, Kasai T, Nagashima S, Noguchi Y, Soda H, Kohno S.
Intern Med      Dec 1997

Conference Activities & Talks

Updated results of phase 1 study of DS-8201a in patinets with HER2 expressing non-breast, non-gastric malignancies
Junji Tsurutani
ESMO   11 Sep 2017   
Metastatic Breast Cancer
Junji Tsurutani
Best of ASCO   Jun 2017   
Personalized medicine in HER2 positive disease
Junji Tsurutani
JSMO   Jul 2016   
Liquid Biopsy
Junji Tsurutani
JSMO   Jul 2015   
Metastatic Breast Cancer
Junji Tsurutani
Best of ASCO   Jun 2015   
Randomized Phase III study of Taxane vs. S-1 in metastatic breast cancer
Junji Tsurutani
Japanese Society of Medical Oncology   Jul 2014   
Phase II study of weekly paclitaxel for relapsed small cell lung cancer.
ASCO   2002   ASCO
A phase Ⅲ、first-line trial of gefitinib versus cisplatin plus docetaxel for patients with advanced or recurrent non-small cell lung cancer (NSCLC) harboring activating mutation of the epidermal growthfactor receptor (EGFR)
34th ESMO   Sep 2009   34th ESMO
Therapeutic Strategy for Breast Cancer in Kinki University
Mar 2012   

Research Grants & Projects

Role of HRG in resistance against anti-HER2 therapy
Ministry of Education, Culture, Sports, Science and Technology: JSPS
Project Year: Apr 2014 - Mar 2017    Investigator(s): Junji Tsurutani